-
Kenya's economy faces climate change risks: World Bank
-
Cash handouts, fare hikes as Philippines battles soaring fuel costs
-
Indonesia weighs response to price pressures from Middle East war
-
In Hollywood, AI's no match for creativity, say top executives
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
Trump vows to 'take' Cuba as island reels from oil embargo
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Nvidia rides 'claw' craze with AI agent platform
-
Damaged Russian tanker has 700 tonnes of fuel on board: Moscow
-
Talks towards international panel to tackle 'inequality emergency' begin at UN
-
EU talks energy as oil price soars
-
Swiss government rejects proposal to limit immigration
-
Ingredients of life discovered in Ryugu asteroid samples
-
Why Iranian drones are hard to stop
-
France threatens to block funds for India over climate inaction
-
"So proud": Irish hometown hails Oscar winner Jessie Buckley
-
European bank battle heats up as UniCredit swoops for Commerzbank
-
Italian bank UniCredit makes bid for Germany's Commerzbank
-
AI to drive growth despite geopolitics, Taiwan's Foxconn says
-
Filipinas seek abortions online in largely Catholic nation
-
'One Battle After Another' wins best picture Oscar
-
South Koreans bask in Oscars triumph for 'KPop Demon Hunters'
-
'One Battle After Another' dominates Oscars
-
Norway's Oscar winner 'Sentimental Value': a failing father seeks redemption
-
Indonesia firms in palm oil fraud probe supplied fuel majors
-
Milan-Cortina Paralympics end as a 'beacon of unity'
-
It's 'Sinners' vs 'One Battle' as Oscars day arrives
-
Oscars night: latest developments
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
-
US mayors push back against data center boom as AI backlash grows
-
Who covers AI business blunders? Some insurers cautiously step up
-
Election campaign deepens Congo's generational divide
-
Courchevel super-G cancelled due to snow and fog
-
Middle East turmoil revives Norway push for Arctic drilling
-
Iran, US threaten attacks on oil facilities
-
Oscars: the 10 nominees for best picture
-
Spielberg defends ballet, opera after Chalamet snub
-
Kharg Island bombed, Trump says US to escort ships through Hormuz soon
-
Jurors mull evidence in social media addiction trial
-
UK govt warns petrol retailers against 'unfair practices' during Iran war
-
Mideast war cuts Hormuz strait transit to 77 ships: maritime data firm
-
How will US oil sanctions waiver help Russia?
-
Oil stays above $100, stocks slide tracking Mideast war
-
How Iranians are communicating through internet blackout
-
Global shipping industry caught in storm of war
-
Why is the dollar profiting from Middle East war?
-
Oil dips under $100, stocks back in green tracking Mideast war
Animal testing put to the test in Swiss vote
Switzerland goes to the polls Sunday to decide whether animal and human testing should be banned -- a proposal that has triggered an outcry in a country heavily reliant on big pharma.
Opinions suggest that the proposal by animal rights defenders is highly unlikely to pass.
But if it did, "Switzerland would be the only country internationally with such a ban," said Yves Fluckiger, president of the Swiss universities lobby group.
Researchers insist that medical progress is impossible without experimentation.
At the University of Geneva, Patrycja Nowak-Sliwinska, head of the molecular pharmacology laboratory, unveils her cell incubator where intestinal organoids from cancer patients are being cultivated.
These structures, made up of cells, make it possible to test a large number of potential treatments.
"With the in vitro model, we try to find promising candidates" -- and only the latter would then be tested on animals, said Nowak-Sliwinska, who received a prize rewarding researchers who work to replace animals with other methods.
But even she said it would be impossible to do all the research without animal experimentation and clinical trials.
This is why the university's Faculty of Medicine has an animal facility in the basement housing some 25,000 animals -- mostly mice and rats.
- Strict protocols -
Inside, Professor Doron Merkler conducts research to find a treatment for a form of multiple sclerosis.
The research could not advance without using mice, into which he injects modified cells to observe how the disease affects the nervous system.
The mouse he is working on is showing symptoms: instability, difficulty moving, and partial paralysis of the limbs.
The experiments are framed by a strict protocol regarding their degree of severity, and animal keepers are trained to detect when an animal is not well.
"If no veterinary care can be provided to the animal, we can decide with the researcher to sacrifice it," said Pierre Bonnaventure, head of animal facilities at the faculty.
In Switzerland, researchers seeking to use live animals must make a formal request, establish that there is no alternative method available and that the conditions imposed on the animals will be as light as possible.
The number of animals used has consequently fallen sharply, from nearly two million per year in the early 1980s to around 560,000.
Some 20,000 animals a year undergo severe interventions, such as the implantation of a tumour, according to federal authorities.
- Proposal 'goes too far' -
Under Switzerland's direct democracy system, campaigners collected enough signatures to trigger a popular vote.
The proposal would outlaw experiments not only on animals but on humans too, as well as ban the importation of new drugs developed through such means.
"Animal experiments should be considered a crime," Renato Werndli, a doctor among those who launched the initiative, told AFP.
All the major political parties in Switzerland are against the proposal.
For the government, the ban "goes too far" and would have "serious consequences for health" -- and also for the economy, in a country where the chemical and pharmaceutical sector represents just over half of all exports.
Interpharma, the Swiss pharmaceutical industry's lobby group, warned that in the event of a ban, "the institutions and companies concerned would be forced to relocate their activities abroad".
Switzerland has already rejected three initiatives on the subject -- in 1985 (70 percent), 1992 (56 percent) and 1993 (72 percent) -- and is expected to do likewise this time.
But it remains to be seen whether the majority will be as big, in a society where animal welfare has grown in importance.
For Samia Hurst, a bioethicist at the University of Geneva, the new initiative commits "a fairly frequent mistake, which is to target biomedical research".
However, she told AFP: "Animal experimentation, among the various uses that humanity makes of other species, is both the most closely monitored and undoubtedly the most justified."
Y.Ponomarenko--CPN